198 related articles for article (PubMed ID: 9690942)
1. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.
Diasio RB
Br J Clin Pharmacol; 1998 Jul; 46(1):1-4. PubMed ID: 9690942
[TBL] [Abstract][Full Text] [Related]
2. [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].
Watabe T; Ogura K; Nishiyama T
Yakugaku Zasshi; 2002 Aug; 122(8):527-35. PubMed ID: 12187768
[TBL] [Abstract][Full Text] [Related]
3. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
4. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
Watabe T; Okuda H; Ogura K
Yakugaku Zasshi; 1997 Nov; 117(10-11):910-21. PubMed ID: 9414600
[TBL] [Abstract][Full Text] [Related]
5. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
Yan J; Tyring SK; McCrary MM; Lee PC; Haworth S; Raymond R; Olsen SJ; Diasio RB
Clin Pharmacol Ther; 1997 May; 61(5):563-73. PubMed ID: 9164418
[TBL] [Abstract][Full Text] [Related]
6. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi K; Watabe T; Ogura Y
Drug Metab Dispos; 1997 Feb; 25(2):270-3. PubMed ID: 9029059
[TBL] [Abstract][Full Text] [Related]
7. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine.
Ogura K; Nishiyama T; Takubo H; Kato A; Okuda H; Arakawa K; Fukushima M; Nagayama S; Kawaguchi Y; Watabe T
Cancer Lett; 1998 Jan; 122(1-2):107-13. PubMed ID: 9464498
[TBL] [Abstract][Full Text] [Related]
8. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.
Nakayama H; Kinouchi T; Kataoka K; Akimoto S; Matsuda Y; Ohnishi Y
Pharmacogenetics; 1997 Feb; 7(1):35-43. PubMed ID: 9110360
[TBL] [Abstract][Full Text] [Related]
9. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Miyauchi S; Imaoka T; Okada T; Motoyama M; Kawaguchi T; Akiyama H; Odomi M
Jpn J Pharmacol; 1996 Feb; 70(2):139-48. PubMed ID: 8866751
[TBL] [Abstract][Full Text] [Related]
10. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi Y; Watabe T
Drug Metab Dispos; 1997 May; 25(5):270-3. PubMed ID: 9152608
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug combination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides.
Machida H; Ashida N; Ikeda T; Sakata S; Baba M; Shigeta S
Antimicrob Agents Chemother; 1992 Jan; 36(1):214-6. PubMed ID: 1317147
[TBL] [Abstract][Full Text] [Related]
12. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
14. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
[TBL] [Abstract][Full Text] [Related]
15. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
Kanamitsu SI; Ito K; Okuda H; Ogura K; Watabe T; Muro K; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):467-74. PubMed ID: 10725316
[TBL] [Abstract][Full Text] [Related]
16. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Balzarini J; Sienaert R; Liekens S; Van Kuilenburg A; Carangio A; Esnouf R; De Clercq E; McGuigan C
Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):21-6; discussion 27. PubMed ID: 11219973
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus.
Kawai H; Yoshida I; Suzutani T
Microbiol Immunol; 1993; 37(11):877-82. PubMed ID: 8295566
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
